

Recombinant Proteinrapapeutics CDMO Market Size, Trends, Analysis, and Outlook By Type (Growth Hormones, Interferons, Vaccines, Immunostimulating Agents, Others), By Source (Mammalian Systems, Microbial Systems, Others), By Indication (Oncology, Infectious Diseases, Immunological Disorders, Metabolic Disorders, Haematological Disorders, Others), by Region, Country, Segment, and Companies, 2024-2030

<https://marketpublishers.com/r/R778F40469C4EN.html>

Date: March 2024

Pages: 190

Price: US\$ 3,980.00 (Single User License)

ID: R778F40469C4EN

Abstracts

The global Recombinant Proteinrapapeutics CDMO market size is poised to register 12.58% growth from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Recombinant Proteinrapapeutics CDMO market across By Type (Growth Hormones, Interferons, Vaccines, Immunostimulating Agents, Others), By Source (Mammalian Systems, Microbial Systems, Others), By Indication (Oncology, Infectious Diseases, Immunological Disorders, Metabolic Disorders, Haematological Disorders, Others).

The Recombinant Protein Therapeutics CDMO market is witnessing robust growth due to the rising demand for biologics, advancements in protein engineering, and outsourcing trends in the pharmaceutical industry. Contract development and manufacturing organizations (CDMOs) play a vital role in providing expertise and infrastructure for the production of recombinant protein therapeutics. With increasing pipeline complexity and the need for flexible manufacturing solutions, the market for CDMO services in recombinant protein therapeutics is expected to continue expanding.

Recombinant Proteinapeutics CDMO Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Recombinant Proteinapeutics CDMO market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Recombinant Proteinapeutics CDMO survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Recombinant Proteinapeutics CDMO industry.

Key market trends defining the global Recombinant Proteinapeutics CDMO demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

Recombinant Proteinapeutics CDMO Market Segmentation- Industry Share, Market Size, and Outlook to 2030

The Recombinant Proteinapeutics CDMO industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Recombinant Proteinapeutics CDMO companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

Key strategies adopted by companies within the Recombinant Proteinapeutics CDMO industry

Leading Recombinant Proteinapeutics CDMO companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Recombinant Proteinapeutics

CDMO companies.

Recombinant Proteinapeutics CDMO Market Study- Strategic Analysis Review

The Recombinant Proteinapeutics CDMO market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.

Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.

Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.

Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

Recombinant Proteinapeutics CDMO Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Recombinant Proteinapeutics CDMO industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.

Recombinant Proteinapeutics CDMO Country Analysis and Revenue Outlook to 2030

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.

North America Recombinant Proteinapeutics CDMO Market Size Outlook- Companies plan for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Recombinant Proteinapeutics CDMO market segments. Similarly, Strong end-user demand is encouraging Canadian Recombinant Proteinapeutics CDMO companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Recombinant Proteinapeutics CDMO market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

Europe Recombinant Proteinapeutics CDMO Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Recombinant Proteinapeutics CDMO industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Recombinant Proteinapeutics CDMO market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

Asia Pacific Recombinant Proteinapeutics CDMO Market Size Outlook- an attractive hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Recombinant Proteinapeutics CDMO in Asia Pacific. In particular, China, India, and South East Asian Recombinant Proteinapeutics CDMO markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in

the region.

Latin America Recombinant Proteinapeutics CDMO Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

Middle East and Africa Recombinant Proteinapeutics CDMO Market Size Outlook- continues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Recombinant Proteinapeutics CDMO market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Recombinant Proteinapeutics CDMO.

Recombinant Proteinapeutics CDMO Market Company Profiles

The global Recombinant Proteinapeutics CDMO market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Batavia Biosciences B.V., BIOVIAN, Catalent Inc, Curia Global Inc, Enzene Biosciences Ltd, FUJIFILM Diosynth Biotechnologies, Halix B.V., Lonza, Richter-Helm BioLogics, WuXi Biologics

Recent Recombinant Proteinapeutics CDMO Market Developments

The global Recombinant Proteinapeutics CDMO market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

Recombinant Proteinapeutics CDMO Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)

Qualitative Analysis

Pricing Analysis

Value Chain Analysis

SWOT Profile

Market Dynamics- Trends, Drivers, Challenges

Porter's Five Forces Analysis

Macroeconomic Impact Analysis

Case Scenarios- Low, Base, High

Market Segmentation:

By Type

Growth Hormones

Interferons

Vaccines

Immunostimulating Agents

Others

By Source

Mammalian Systems

Microbial Systems

Others

By Indication

Oncology

Infectious Diseases

Immunological Disorders

Metabolic Disorders

Haematological Disorders

Others

Geographical Segmentation:

North America (3 markets)

Europe (6 markets)

Asia Pacific (6 markets)

Latin America (3 markets)

Middle East Africa (5 markets)

Companies

Batavia Biosciences B.V.

BIOVIAN

Catalent Inc

Curia Global Inc

Enzene Biosciences Ltd

FUJIFILM Diosynth Biotechnologies

Halix B.V.

Lonza

Richter-Helm BioLogics

WuXi Biologics

Formats Available: Excel, PDF, and PPT

Contents

1. EXECUTIVE SUMMARY

- 1.1 Recombinant Proteinapeutics CDMO Market Overview and Key Findings, 2024
- 1.2 Recombinant Proteinapeutics CDMO Market Size and Growth Outlook, 2021- 2030
- 1.3 Recombinant Proteinapeutics CDMO Market Growth Opportunities to 2030
- 1.4 Key Recombinant Proteinapeutics CDMO Market Trends and Challenges
 - 1.4.1 Recombinant Proteinapeutics CDMO Market Drivers and Trends
 - 1.4.2 Recombinant Proteinapeutics CDMO Market Challenges
- 1.5 Competitive Landscape and Key Players
- 1.6 Competitive Analysis- Growth Strategies Adopted by Leading Recombinant Proteinapeutics CDMO Companies

2. RECOMBINANT PROTEINRAPEUTICS CDMO MARKET SIZE OUTLOOK TO 2030

- 2.1 Recombinant Proteinapeutics CDMO Market Size Outlook, USD Million, 2021-2030
- 2.2 Recombinant Proteinapeutics CDMO Incremental Market Growth Outlook, %, 2021- 2030
- 2.3 Segment Snapshot, 2024

3. RECOMBINANT PROTEINRAPEUTICS CDMO MARKET- STRATEGIC ANALYSIS REVIEW

- 3.1 Porter's Five Forces Analysis
 - * Threat of New Entrants
 - * Threat of Substitutes
 - * Intensity of Competitive Rivalry
 - * Bargaining Power of Buyers
 - * Bargaining Power of Suppliers
- 3.2 Value Chain Analysis
- 3.3 SWOT Analysis

4. RECOMBINANT PROTEINRAPEUTICS CDMO MARKET SEGMENTATION ANALYSIS AND OUTLOOK

- 4.1 Market Segmentation and Scope
- 4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030

By Type

Growth Hormones

Interferons

Vaccines

Immunostimulating Agents

Others

By Source

Mammalian Systems

Microbial Systems

Others

By Indication

Oncology

Infectious Diseases

Immunological Disorders

Metabolic Disorders

Haematological Disorders

Others

4.3 Growth Prospects and Niche Opportunities, 2023- 2030

4.4 Regional comparison of Market Growth, CAGR, 2023-2030

5. REGION-WISE MARKET OUTLOOK TO 2030

5.1 Key Findings for Asia Pacific Recombinant Proteinapeutics CDMO Market, 2025

5.2 Asia Pacific Recombinant Proteinapeutics CDMO Market Size Outlook by Type, 2021- 2030

5.3 Asia Pacific Recombinant Proteinapeutics CDMO Market Size Outlook by Application, 2021- 2030

5.4 Key Findings for Europe Recombinant Proteinapeutics CDMO Market, 2025

5.5 Europe Recombinant Proteinapeutics CDMO Market Size Outlook by Type, 2021- 2030

5.6 Europe Recombinant Proteinapeutics CDMO Market Size Outlook by Application, 2021- 2030

5.7 Key Findings for North America Recombinant Proteinapeutics CDMO Market, 2025

5.8 North America Recombinant Proteinapeutics CDMO Market Size Outlook by Type, 2021- 2030

5.9 North America Recombinant Proteinapeutics CDMO Market Size Outlook by Application, 2021- 2030

5.10 Key Findings for South America Recombinant Proteinapeutics CDMO Market, 2025

5.11 South America Pacific Recombinant Proteinapeutics CDMO Market Size Outlook by Type, 2021- 2030

5.12 South America Recombinant Proteinapeutics CDMO Market Size Outlook by Application, 2021- 2030

5.13 Key Findings for Middle East and Africa Recombinant Proteinapeutics CDMO Market, 2025

5.14 Middle East Africa Recombinant Proteinapeutics CDMO Market Size Outlook by Type, 2021- 2030

5.15 Middle East Africa Recombinant Proteinapeutics CDMO Market Size Outlook by Application, 2021- 2030

6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030

6.1 US Recombinant Proteinapeutics CDMO Market Size Outlook and Revenue Growth Forecasts

6.2 US Recombinant Proteinapeutics CDMO Industry Drivers and Opportunities

6.3 Canada Market Size Outlook and Revenue Growth Forecasts

6.4 Canada Recombinant Proteinapeutics CDMO Industry Drivers and Opportunities

6.6 Mexico Market Size Outlook and Revenue Growth Forecasts

6.6 Mexico Recombinant Proteinapeutics CDMO Industry Drivers and Opportunities

6.7 Germany Market Size Outlook and Revenue Growth Forecasts

6.8 Germany Recombinant Proteinapeutics CDMO Industry Drivers and Opportunities

6.9 France Market Size Outlook and Revenue Growth Forecasts

6.10 France Recombinant Proteinapeutics CDMO Industry Drivers and Opportunities

6.11 UK Market Size Outlook and Revenue Growth Forecasts

6.12 UK Recombinant Proteinapeutics CDMO Industry Drivers and Opportunities

6.13 Spain Market Size Outlook and Revenue Growth Forecasts

6.14 Spain Recombinant Proteinapeutics CDMO Industry Drivers and Opportunities

6.16 Italy Market Size Outlook and Revenue Growth Forecasts

6.16 Italy Recombinant Proteinapeutics CDMO Industry Drivers and Opportunities

6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts

6.18 Rest of Europe Recombinant Proteinapeutics CDMO Industry Drivers and Opportunities

6.19 China Market Size Outlook and Revenue Growth Forecasts

6.20 China Recombinant Proteinapeutics CDMO Industry Drivers and Opportunities

6.21 India Market Size Outlook and Revenue Growth Forecasts

6.22 India Recombinant Proteinapeutics CDMO Industry Drivers and Opportunities

6.23 Japan Market Size Outlook and Revenue Growth Forecasts

6.24 Japan Recombinant Proteinapeutics CDMO Industry Drivers and Opportunities

- 6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
- 6.26 South Korea Recombinant Proteinapeutics CDMO Industry Drivers and Opportunities
- 6.27 Australia Market Size Outlook and Revenue Growth Forecasts
- 6.28 Australia Recombinant Proteinapeutics CDMO Industry Drivers and Opportunities
- 6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
- 6.30 South East Asia Recombinant Proteinapeutics CDMO Industry Drivers and Opportunities
- 6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
- 6.32 Rest of Asia Pacific Recombinant Proteinapeutics CDMO Industry Drivers and Opportunities
- 6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
- 6.34 Brazil Recombinant Proteinapeutics CDMO Industry Drivers and Opportunities
- 6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
- 6.36 Argentina Recombinant Proteinapeutics CDMO Industry Drivers and Opportunities
- 6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
- 6.38 Rest of South America Recombinant Proteinapeutics CDMO Industry Drivers and Opportunities
- 6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
- 6.40 Middle East Recombinant Proteinapeutics CDMO Industry Drivers and Opportunities
- 6.41 Africa Market Size Outlook and Revenue Growth Forecasts
- 6.42 Africa Recombinant Proteinapeutics CDMO Industry Drivers and Opportunities

7. RECOMBINANT PROTEINRAPEUTICS CDMO MARKET OUTLOOK ACROSS SCENARIOS

- 7.1 Low Growth Case
- 7.2 Reference Growth Case
- 7.3 High Growth Case

8. RECOMBINANT PROTEINRAPEUTICS CDMO COMPANY PROFILES

- 8.1 Profiles of Leading Recombinant Proteinapeutics CDMO Companies in the Market
 - 8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
 - 8.3 Financial Performance and Key Metrics
- Batavia Biosciences B.V.
BIOVIAN
Catalent Inc

Curia Global Inc
Enzene Biosciences Ltd
FUJIFILM Diosynth Biotechnologies
Halix B.V.
Lonza
Richter-Helm BioLogics
WuXi Biologics

9. APPENDIX

9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information

I would like to order

Product name: Recombinant Proteinapeutics CDMO Market Size, Trends, Analysis, and Outlook By Type (Growth Hormones, Interferons, Vaccines, Immunostimulating Agents, Others), By Source (Mammalian Systems, Microbial Systems, Others), By Indication (Oncology, Infectious Diseases, Immunological Disorders, Metabolic Disorders, Haematological Disorders, Others), by Region, Country, Segment, and Companies, 2024-2030

Product link: <https://marketpublishers.com/r/R778F40469C4EN.html>

Price: US\$ 3,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R778F40469C4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970